Advertisements


Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

Theravance (TBPH) submits the NDA for its key c.....»»

Category: topSource: zacksNov 14th, 2017

Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

Theravance (TBPH) submits the NDA for its key c.....»»

Category: topSource: zacksNov 14th, 2017

Theravance"s NDA for COPD Candidate Gets FDA Acceptance

The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018. Theravance Biopharma, Inc. T.....»»

Category: dealsSource: nytJan 30th, 2018

Theravance/Mylan Presents Phase III Data on COPD Candidate

Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safe.....»»

Category: topSource: zacksMay 24th, 2017

Theravance Shares Rise on Approval of Glaxo"s COPD Therapy

Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy. Theravance Biopha.....»»

Category: smallbizSource: nytNov 17th, 2017

Mylan, Theravance announce successful phase III studies for COPD drug

Milan Pharmaceuticals (Nasdaq:MYL) announced today that a drug it is helping develop in partnership with Theravance Biopharma, Inc. (Nasdaq: TBPH) has shown promise in two Phase III efficacy studies treating patients with chronic obstructive pulmonary dis.....»»

Category: topSource: bizjournalsOct 20th, 2016

Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly .....»»

Category: smallbizSource: nytFeb 8th, 2018

Janssen Pharmaceutical unit enters into a global collaboration with an affiliate of Theravance Biopharma (TBPH)

Janssen Pharmaceutical unit enters into a global collaboration with an affiliate of Theravance Biopharma (TBPH).....»»

Category: topSource: seekingalphaFeb 7th, 2018

TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

Zacks.....»»

Category: topSource: redinewsDec 29th, 2017

TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vas.....»»

Category: personnelSource: nytDec 29th, 2017

Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.

Agios (AGIO) submits new drug a.....»»

Category: worldSource: nytDec 27th, 2017

Theravance Biopharma Enters Oversold Territory (TBPH)

Dividend Channel.....»»

Category: topSource: redinewsDec 6th, 2017

Theravance Shares Rise on Approval of Glaxo"s COPD Therapy

Zacks.....»»

Category: topSource: redinewsNov 18th, 2017

Your Daily Pharma Scoop: Heron Undervalued, Theravance Submits NDA, Nektar Continues To Surge

Your Daily Pharma Scoop: Heron Undervalued, Theravance Submits NDA, Nektar Continues To Surge.....»»

Category: topSource: seekingalphaNov 14th, 2017

Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States. Teva Pharmaceutical Industries.....»»

Category: worldSource: nytOct 19th, 2017

Theravance Biopharma (TBPH) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

Theravance Biopharma (TBPH) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow.....»»

Category: topSource: seekingalphaSep 27th, 2017

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q2 2017 Results - Earnings Call Transcript

Theravance Biopharma"s (TBPH) CEO Rick Winningham on Q2 2017 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaAug 12th, 2017

Theravance Biopharma Inc (TBPH) CEO Rick E Winningham Bought $—45,……… of Shares

Related Stocks: TBPH,.....»»

Category: dealsSource: nytAug 11th, 2017

Theravance Biopharma (TBPH) Updates On Results From Phase 2b Study Of Velusetrag - Slideshow

Theravance Biopharma (TBPH) Updates On Results From Phase 2b Study Of Velusetrag - Slideshow.....»»

Category: topSource: seekingalphaAug 3rd, 2017

Cardiome"s Partner SteadyMed Submits NDA for PAH Injection

Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH.....»»

Category: topSource: zacksJul 4th, 2017

Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?

Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. .....»»

Category: topSource: zacksJun 13th, 2017